FindTrial
Sign In

Retrospective Study to assess the Prevalence and Treatment of Dyslipidemia in Indian Patients

Retrospective Observational EMR based Real World Study to assess the Prevalence and Treatment of Dyslipidemia in Indian Patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/09/057954
Enrollment
10000
Registered
2023-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: NIl: Nil

Sponsors

Dr Reddys Laboratories Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Dyslipidemia patients

Exclusion criteria

Exclusion criteria: Patients not diagnosed with dyslipidemia.

Design outcomes

Primary

MeasureTime frame
Prevalence of dyslipidemia. Incidence of newly diagnosed dyslipidemia.Timepoint: A follow-up data will be captured at 3 months ±30 days from the baseline visit/index date per patient to assess the change in lipid levels over time.—

Secondary

MeasureTime frame
Levels of TC, LDL, HDL, VLDL, & serum TG in newly diagnosed dyslipidemia patients with different concurrent conditions at baseline & follow-up. Number & percentage of newly diagnosed dyslipidemia patients achieving target LDL levels according to international guidelines and LAI consensus statement.Timepoint: Outcome analysis will be done for the patients who have a follow up visit within 10-30 days from prescription of amlodipine or its combinations.—

Countries

India

Contacts

Public ContactDr Rahul Rathod

Dr Reddys Laboratories Limited

mujtabanaqvi@drreddys.com7032969523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026